Wall Street Transcript Interview with Enzo Biochem, Inc. (ENZ) President, Treasurer, and Chief Financial Officer Barry W. Weiner and Vice President, Corporate Development and Interim President of Enzo Clinical Labs, David C. Goldberg

Wall Street Transcript

67 WALL STREET, New York - August 29, 2012 - The Wall Street Transcript has just published its Medical Research, Diagnostic Substances and Life Science Tools Report offering a timely review of the sector to serious investors and industry executives. This special feature contains expert industry commentary through in-depth interviews with public company CEOs, Equity Analysts and Money Managers. The full issue is available by calling (212) 952-7433 or via The Wall Street Transcript Online.

Topics covered: Health Care Consolidation Activity - Cost Reduction and Improving Efficiencies - Chinese CRO Growth - NIH Budget Uncertainty

Companies include: Enzo Biochem Inc. (ENZ) and many others.

In the following excerpt from the Medical Research, Diagnostic Substances and Life Science Tools Report, the President and the Vice President of Corporate Development of Enzo Biochem discuss the outlook for their company for investors:

TWST: Would you start with a brief historical sketch of the company and a picture its operations at the present time?

Mr. Weiner: Enzo is focused in the area of gene labeling, gene identification and related research products. We're focused at driving research in the immunological and nucleic acid diagnostic and research space. We are an integrated life sciences company.

In addition to developing, manufacturing and marketing research reagents, products and systems for the global marketplace, we have a significant, closely aligned clinical laboratory organization that supports the developmental efforts of our life sciences unit. It is able to do so because Enzo Clinical Labs is one of the largest independent clinical labs serving physicians from New York to the Philadelphia area, New Jersey and parts of lower Connecticut.

The integrated structure of Enzo has evolved to become a very formidable business entity. We have the capabilities today to engage in fundamental, basic biological and biomarker research, and to carry those products and/or platforms through a developmental and commercialization process. That allows us to market products globally and to physicians in our region, as well as to support the efforts for more advanced development and regulatory approval on the state, federal and international levels.

We also have a therapeutics venture with several products in development. One is currently in a Phase II trial with the National Institutes of Health. It targets the treatment of autoimmune uveitis, which is an inflammation of the inner eye and one of the leading causes of blindness.

We also have a very extensive intellectual property platform which impacts many areas in the field of diagnostics and modern genomics. We are credited as a developer of some very key platforms, including the Hybrid Capture platform, which drives the QIAGEN HPV test, and the branched DNA platform, which provides significant utility in a number of viral load tests. Recently, we have been developing a novel platform for DNA amplification, or nucleic acid amplification. We call it AmpiProbe, and it provides the potential to be a low-cost alternative for reagents used in PCR-based system.

TWST: Would you give us a sense of where Enzo Biochem's pipeline stands at the moment? What are some of the key steps the company needs to take in the near-to-mid term?

For more from this interview and many others visit the Wall Street Transcript - a unique service for investors and industry researchers - providing fresh commentary and insight through verbatim interviews with CEOs and research analysts. This special issue is available by calling (212) 952-7433 or via The Wall Street Transcript Online.

View Comments